Vertex Pharmaceuticals

VRTX · NASDAQ · USD

$504.73−0.40%−$2.01

Close · October 2, 2026

At a glance

Revenue growth
+8.90%
2025 vs 2024
Net margin
32.9%
2024: -4.9%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total revenue3,3342,9873,1903,0762,9652,7702,9122,7722,6462,6912,5182,484
Cost of revenue1,4831,3541,4401,3931,3861,3431,4221,2691,3391,1321,1931,129
Gross profit1,8511,6331,7501,6841,5791,4281,4901,5031,3071,5591,3251,355
Selling, general and administrative582494487445425396378372372343369264
Research and development9949621,107978978———————
Operating income1,2691,1391,2631,2391,1541,0311,1121,1329351,2169561,091
EBIT1,2691,1391,2631,2391,1541,0311,1121,1329351,2169561,091
EBITDA1,3251,1951,2881,2931,2061,0801,1341,1859891,2701,0031,133
Interest expense——3.33.33.73.02.87.59.910.410.610.9
Pre-tax income1,3921,2531,3311,2991,2837301,1371,224-3,3911,2791,1481,179
Income tax29222214021625084.1224179202180179144
Net income1,1001,0311,1911,0831,0336469131,045-3,5941,1009691,035
Net income to common shareholders1,1001,0311,1911,0831,0336469131,045-3,5941,1009691,035
Basic EPS4.344.064.694.244.022.523.554.05-13.924.263.764.01
Diluted EPS4.314.024.654.203.992.493.504.01-13.924.213.713.97
Average shares (basic)254254254256257257258258258258258258
Average shares (diluted)255256256258259260261261258261261261